AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia (HR-MDS/CMML).
Higher Risk Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia
DRUG: AMG 176|DRUG: Azacitidine
Part 1A and 1B: Number of Participants Who Experience a Dose Limiting Toxicity (DLT), Day 1 to Day 28|Part 1A and 1B: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE), Up to 1.5 years|Part 2: Overall Response Rate (ORR), As assessed according to the Uniform Response Criteria for Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)., Up to 1.5 years
Part 1A and Part 1B: Overall Response, As assessed according to the Uniform Response Criteria for MDS/MPN for R/R MDS/CMML participants., Up to 1.5 years|Part 1A, Part 1B and Part 2: Event-free Survival (EFS), Up to 1.5 years|Part 1A and Part 1B: Time to Response (TTR), Up to 1.5 years|Part 1A, Part 1B and Part 2: Duration of Response (DoR), Up to 1.5 years|Part 1A: Maximum Concentration (Cmax) of AMG 176 when Administered as Monotherapy, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1A: Area Under the Concentration-time Curve (AUC) of AMG 176 when Administered as Monotherapy, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1A: Clearance (CL) of AMG 176 when Administered as Monotherapy, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1A: Half-life (t1/2) of AMG 176 when Administered as Monotherapy, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1B and Part 2: Cmax of AMG 176 when Administered in Combination, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1B and Part 2: AUC of AMG 176 when Administered in Combination, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1B and Part 2: CL of AMG 176 when Administered in Combination, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1B and Part 2: T1/2 of AMG 176 when Administered in Combination, Cycle 1 (=23 days) Day 1 and Day 8: Pre-dose and 0.5, 3, 5, 7, 8, 12 (Day 8 only) and 24 hours post-dose. Day 15 and 22: Pre-dose and 0.5, 8 and 24 hours post-dose. Cycle 2-4 (=23 days) Day 1: Pre-dose and 0.5 and 24 hours post-dose|Part 1B and Part 2: Cmax of Azacitidine when Administered in Combination, Cycle 1 (=23 days) Day 1: Pre-dose, 5 mins post-dose, 30 mins post-dose, 1, 2, 4, and 8 hours post-dose.|Part 1B and Part 2: AUC of Azacitidine when Administered in Combination, Cycle 1 (=23 days) Day 1: Pre-dose, 5 mins post-dose, 30 mins post-dose, 1, 2, 4, and 8 hours post-dose.|Part 1B and Part 2: CL of Azacitidine when Administered in Combination, Cycle 1 (=23 days) Day 1: Pre-dose, 5 mins post-dose, 30 mins post-dose, 1, 2, 4, and 8 hours post-dose.|Part 1B and Part 2: T1/2 of Azacitidine when Administered in Combination, Cycle 1 (=23 days) Day 1: Pre-dose, 5 mins post-dose, 30 mins post-dose, 1, 2, 4, and 8 hours post-dose.|Part 2: Time to Transformation to Acute Myeloid Leukemia (AML), Up to 1.5 years|Part 2: Overall Survival (OS), Up to 1.5 years|Part 2: Time to Next MDS Treatment (TTNT), Up to 1.5 years
This study is a Phase 1 clinical trial designed to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of HR-MDS/CMML. Participants will be treated with intravenous (IV) AMG 176 and IV or subcutaneous (SC) azacitidine.